Quantifying the Reversibility of Clofazimine-induced Pigmentation in a Patient with Mycobacterium abscessus Pulmonary Disease.

Masashi Ito, Fumiya Watanabe, Koji Furuuchi, Keiji Fujiwara, Tatsuya Kodama, Takashi Ohe, Yoshiaki Tanaka, Takashi Yoshiyama, Ken Ohta, Kozo Morimoto
Author Information
  1. Masashi Ito: Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
  2. Fumiya Watanabe: Department of Pharmacometrics and Pharmacokinetics, Meiji Pharmaceutical University, Japan.
  3. Koji Furuuchi: Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
  4. Keiji Fujiwara: Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
  5. Tatsuya Kodama: Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
  6. Takashi Ohe: Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
  7. Yoshiaki Tanaka: Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
  8. Takashi Yoshiyama: Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
  9. Ken Ohta: Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
  10. Kozo Morimoto: Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.

Abstract

A 45-year-old woman with Mycobacterium abscessus pulmonary disease was treated with multidrug therapy, including clofazimine, at Fukujuji Hospital. Six months after clofazimine initiation, the treatment was discontinued at the patient's request due to hyperpigmentation. Pigmentation is a critical side effect of clofazimine. We quantified clofazimine-induced pigmentation on her face using NeoVoirI and measured the serum concentration of clofazimine during the administration period. The patient's skin tone score closely correlated with the serum concentration of clofazimine. However, 14 months after the discontinuation of clofazimine, clofazimine-induced pigmentation was still not completely resolved.

Keywords

Word Cloud

Created with Highcharts 10.0.0clofazimineMycobacteriumabscessuspigmentationmonthspatient'sPigmentationclofazimine-inducedserumconcentration45-year-oldwomanpulmonarydiseasetreatedmultidrugtherapyincludingFukujujiHospitalSixinitiationtreatmentdiscontinuedrequestduehyperpigmentationcriticalsideeffectquantifiedfaceusingNeoVoirImeasuredadministrationperiodskintonescorecloselycorrelatedHowever14discontinuationstillcompletelyresolvedQuantifyingReversibilityClofazimine-inducedPatientPulmonaryDiseaseaviumcomplexnontuberculousmycobacteria

Similar Articles

Cited By

No available data.